TCGA-AN-A0FZ-01A-11R-A034-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 0
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.340
- ESTROGEN_RESPONSE_EARLY+0.320
- TGF_BETA_SIGNALING+0.270
- ANGIOGENESIS+0.200
- PI3K_AKT_MTOR_SIGNALING+0.200
- BILE_ACID_METABOLISM+0.190
- PEROXISOME+0.190
- MITOTIC_SPINDLE+0.180
- WNT_BETA_CATENIN_SIGNALING+0.170
- ESTROGEN_RESPONSE_LATE+0.160
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.500
- IL6_JAK_STAT3_SIGNALING-0.390
- INFLAMMATORY_RESPONSE-0.380
- INTERFERON_GAMMA_RESPONSE-0.370
- TNFA_SIGNALING_VIA_NFKB-0.370
- COMPLEMENT-0.290
- IL2_STAT5_SIGNALING-0.290
- KRAS_SIGNALING_UP-0.270
- INTERFERON_ALPHA_RESPONSE-0.260
- KRAS_SIGNALING_DN-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-C8-A3M8-01A-11R-A213-07 | — | B | 0.821 |
| 2 | TCGA-AR-A1AV-01A-21R-A12P-07 | — | B | 0.805 |
| 3 | TCGA-A8-A08O-01A-21R-A056-07 | — | B | 0.804 |
| 4 | TCGA-C8-A26Z-01A-11R-A16F-07 | — | B | 0.777 |
| 5 | TCGA-B6-A0I8-01A-11R-A034-07 | — | B | 0.776 |
| 6 | TCGA-D8-A1X7-01A-11R-A14M-07 | — | B | 0.774 |
| 7 | TCGA-BH-A0E7-01A-11R-A034-07 | — | B | 0.764 |
| 8 | SRR25617914 | — | C | 0.759 |
| 9 | 959c268c-637f-4f39-a254-a505c57e8448 | — | — | 0.745 |
| 10 | TCGA-E2-A1IE-01A-11R-A13Q-07 | — | B | 0.737 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.340 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.320 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.270 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.180 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.160 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.140 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.130 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.090 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.080 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.060 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.060 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.050 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.040 | Inavolisib | — uncovered |